Leerink upgraded Beam Therapeutics (BEAM) to Outperform from Market Perform with a price target of $39, up from $27. The firm notes that prior to Tuesday’s BEAM-101 data in sickle-cell disease, risk of a safety signal kept Leerink on the sidelines. Following disclosure of a patient death, shares opened down over 10%, but recovered over the day, as focus shifted to BEAM-301 data in alpha-1 antitrypsin deficiency, where the firm sees a far more attractive risk/reward. Leerink takes this opportunity to step back in positively after a period of uninspiring stock performance given strong product/market-fit for in vivo single-point mutation base editing in AATD, and potential to address both lung and liver manifestations.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BEAM:
- Beam Therapeutics Reports Steady Progress in Q3 2024
- Cathie Wood’s ARK Investment buys 162.5K shares of Beam Therapeutics today
- Beam could see significant upside over next 6-12 months, says Wedbush
- Beam says patient death determined by investigator to be unrelated to BEAM-101
- Beam Therapeutics to present data on BEAM-101, BEAM-201 at ASH meeting
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
